Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or Combined With Ruxolitinib, in Patients With Myelofibrosis

NCT04218071 is registered in ClinicalTrials.gov with Actuate Therapeutics Inc. as lead sponsor.

NCT NCT04218071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04218071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or Combined With Ruxolitinib, in Patients With Myelofibrosis
Lead sponsor
Actuate Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 20, 2020
Completion date
January 18, 2024
Enrollment
17 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis